By continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our Cookie Policy.
Innovation Powers Us
Better Care Drives Us
Overview
Committed to Innovation
Dedicated to Improving Patients' Lives
MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, biotherapeutic solutions for tissue repair and regeneration.
Our strategy leverages our enzymatic technology platform, focused on next-generation bio active therapies for burn, wound care and tissue repair.
NexoBrid, our commercial orphan biological product for eschar removal of severe thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours and does not harm surrounding viable tissue.
Nexobrid is currently marketed in the European Union as well as in other International markets and is at registration stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).
EscharEx, our next-generation bioactive topical therapy for debridement of chronic and hard-to-heal wounds, is a product candidate in advanced stages of development. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, with only a few daily applications.
MW005, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.
Our Culture
Our People. Our Values. Our Culture
We believe that a great part of our success is fueled by our people and our values. Our culture is the compass for our day to day operations and our people navigate the way, creating the greatest value to our stakeholders.
- We care
- We innovate
- We deliver
- We learn
As a company, we are committed to the highest ethical principles and respect for the individual. We invest in our people, helping them develop, grow and appreciate the valuable resources they are.
We strive for technological and scientific leadership. We are dedicated to redefining the standard of care through our novel bio-therapeutics.
We place a high value on our customers and are focused on delivering patient satisfaction and better outcomes. We endeavor to be a reliable and agile partner that goes the extra mile to meet their customers’ needs, enabling them to achieve their goals.
As a learning organization, we continuously learn from those around us to improve ourselves. We seek to achieve leadership in everything we do, both as individuals and collectively as a company.
“At MediWound, great teams take great ideas and make them happen. We are here to make a difference in standard of care. We think about the many tomorrows our patients can enjoy, always seeking to create a better life for them”
"I take enormous pleasure in knowing that my goal of making NexoBrid available to all patients has come to fruition, changing burn care for thousands of patients worldwide. For me, as a physician, to be able to leave this footprint in medicine is the greatest possible reward"
The Full Solution
A Fully-Integrated Biopharmaceutical Company
MediWound has extensive history and experience developing, manufacturing, and commercializing regenerative medicinal products
RESEARCH & DEVELOPMENT
In-house Expertise
- In-vitro and In-vivo models
- Analytical methods development
- Product formulation
- Clinical development and data generation
- Regulatory processes
MANUFACTURING
State of the Art Facility
- cGMP certified
- Experienced team
- Capable of aseptic processing for sterile products
- Product Development manufacturing suites
Commercialization
Wide global network
- EU direct sales force
- Multiple distribution agreements
- Extensive worldwide supply chain
Our Team
Our People: Leading Change
- Management
- Board of Directors
Sharon Malka
Chief Executive Officer
Lior Rosenberg
Chief Medical Technology Officer
Ety Klinger
Chief R&D Officer
Boaz Gur-Lavie
Chief Financial Officer
Yaron Meyer
Executive Vice President & General Counsel
Andrey Kon
VP Plant Manager
Keren David-Zarbiv
VP Clinical Affairs
Roni Solomon
VP Finance
Eilon Asculai
VP R&D
Smadar Nestor
VP Regulatory Affairs
Nimrod Leuw
VP Quality
Stephen T. Wills
Executive Chairman
Ofer Gonen
Board Member
Vickie R Driver
Board Member
Sharon Kochan
Board Member
Nissim Mashiach
Board Member
Assaf Segal
Board Member
David Fox
Board Member
Samuel Moed
Board Member
Testimonials
Patients' Stories and Physicians' Experience
Lee-Anne Jones
was treated witn NexoBrid
Prof. Dr. Jan Plock & Dr. Frank Sander
speak on their experince with NexoBrid
Join Us
Come work with us
A collaborative, focused, and creative environment
We are focused on seeking cures and advancing care. Join us and together we can influence patient outcomes and quality of care.